Study links oral DHA to airway immune changes in healthy horses

A new study in the American Journal of Veterinary Research adds fresh evidence that oral DHA supplementation can change immune-cell metabolism in the equine lung, even in horses without overt respiratory disease. Researchers reported that 45 days of an algae-derived DHA supplement altered alveolar macrophage metabolism, as well as protein and lipid profiles in bronchoalveolar lavage fluid, in healthy adult horses. The work comes from North Carolina State University and focuses on a question with practical relevance for equine clinicians: whether nutritional modulation can influence airway biology before or alongside clinical disease. (repository.lib.ncsu.edu)

That question has been building for years. Equine asthma and other chronic lower-airway inflammatory conditions are common, and prior studies have suggested omega-3 polyunsaturated fatty acids may help reduce airway inflammation, especially when combined with environmental control such as a low-dust diet. A 2015 study, for example, found omega-3 supplementation provided additional benefit to low-dust management in horses with chronic lower-airway inflammatory disease. At the same time, macrophage biology has drawn growing interest in equine respiratory medicine because alveolar macrophages help shape both inflammatory and resolution pathways in the lung. (pmc.ncbi.nlm.nih.gov)

In the new study, investigators enrolled 10 healthy, university-owned adult horses, though three were removed for unrelated anti-inflammatory drug use, leaving seven that completed the protocol. The design was prospective, sequential, and placebo-controlled: horses underwent bronchoalveolar lavage at baseline, after 45 days of placebo, and after 45 days of DHA supplementation, with a 14-day washout between phases. The test product was Aleira, given at 30 g daily; that dose included 1,500 mg DHA, plus methylsulfonylmethane, mushroom blend, and ascorbic acid. Compared with placebo, DHA supplementation significantly decreased the whole-blood omega-6-to-omega-3 ratio and increased the DHA-to-arachidonic acid ratio. BAL cytology did not significantly change overall, but alveolar macrophage basal and maximal oxygen consumption increased, and lower-airway protein and lipid profiles shifted. (repository.lib.ncsu.edu)

The authors interpret those metabolic changes cautiously but optimistically. In the dissertation version of the work, they write that the shift in macrophage metabolism “may indicate” a greater population of anti-inflammatory, M2-like alveolar macrophages, though they also note that future studies should combine metabolic analysis with direct macrophage phenotyping. That restraint matters. This was a small study in healthy horses, and the supplement was a combination product rather than purified DHA alone, which makes it harder to attribute every observed effect to DHA by itself. (repository.lib.ncsu.edu)

Outside this paper, the broader literature gives the findings some context. Reviews of equine airway inflammation describe omega-3 fatty acids, including DHA, as a plausible adjunct because of their effects on inflammatory lipid mediators, while experimental and translational lung research in other species has linked high-DHA diets to reduced arachidonic acid levels and altered inflammatory responses after dust exposure. That doesn’t prove clinical benefit in horses with asthma, but it supports the biological plausibility behind the new findings. (mdpi.com)

Why it matters: For veterinary professionals, this study is less about changing treatment protocols tomorrow and more about strengthening the mechanistic case for nutritional intervention in equine respiratory care. If DHA can shift macrophage metabolism and airway lipid signaling in healthy horses, it may help explain why some omega-3 strategies appear useful in horses with inflammatory airway disease. Still, the practical takeaway is measured: supplementation should not be viewed as a stand-alone substitute for environmental management, diagnostic workup, or established anti-inflammatory therapy. The study’s size, healthy-horse population, and combination-product design all limit direct clinical extrapolation. (repository.lib.ncsu.edu)

What to watch: The key next question is whether these biomarker and metabolic shifts hold up in larger, controlled trials involving horses with mild/moderate or severe equine asthma, and whether they translate into outcomes clinicians care about, including cough scores, BAL cytology, lung function, medication needs, and performance. Given the authors’ emphasis on future phenotyping work, follow-on studies may also clarify whether DHA is truly pushing airway macrophages toward a more pro-resolving state, or whether the observed effects reflect a broader change in the lower-airway milieu. (repository.lib.ncsu.edu)